home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

341.85 +8.85 (+2.66%)

Streaming Delayed Price Updated: 11:45 AM EDT, Apr 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

21 22 Next >

3 Biotech Stocks to Buy on the Dip: March 2024 ↗

March 27, 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Via InvestorPlace

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

March 20, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years ↗

March 18, 2024

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alnylam Pharmaceuticals's Earnings Outlook ↗

February 14, 2024

Via Benzinga

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest ↗

February 06, 2024

Via Benzinga

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

March 13, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗

March 09, 2024

This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...

Via Talk Markets

Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges ↗

March 05, 2024

Alnylam's KARDIA-2 Phase 2 study on zilebesiran, an RNAi therapeutic for hypertension. Clinically significant reductions in blood pressure observed, with optimistic outlook on upcoming ACC event.

Via Benzinga

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

March 05, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 29, 2024

Via Benzinga

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

February 28, 2024

Via Benzinga

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

February 27, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Via Investor's Business Daily

Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To Know ↗

February 16, 2024

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday? ↗

February 15, 2024

Alnylam Pharmaceuticals' updates on HELIOS-B Phase 3 study and FDA clearance for ALN-APP Phase 1 study. Fiscal year 2024 guidance of $1.4 billion–$1.5 billion in combined net product revenues.

Via Benzinga

Why Alnylam Pharmaceuticals Stock Is Sinking Today ↗

February 15, 2024

Alnylam's change to a key clinical trial design appears to have worried investors more than a small Q4 revenue miss.

Via The Motley Fool

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

February 15, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results

January 29, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again ↗

January 12, 2024

There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.

Via Investor's Business Daily

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

January 09, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates

January 07, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs ↗

January 04, 2024

A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

January 02, 2024

Via Benzinga

Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗

December 29, 2023

Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.

Via Benzinga

Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗

December 22, 2023

Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am

Via Benzinga

Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day

December 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 biotech powerhouses poised to thrive amid sector rebound

December 08, 2023

If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.

Via MarketBeat

Topics ETFs

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com